Skip to main content
European Commission logo print header

Role of Class IIa Histone deacetylases in hematopoietic cell differentiation


Chromatin, the higher order structure of DNA and protein, forms a barrier for gene transcription. Modification of histones, a major component of the chromatin, is a critical mechanism by which the barrier is regulated. An important modification, which is thought to activate transcription, is the acetylation of histones. Regulation of histones acetylation is performed by the antagonistic activities of histone acetyltransferases (HATs) and histone deacetylases (HDACs). Mammalian HDACs are divided into three distinct classes based on their homology to yeast proteins. Class I HDACs (HDAC1, 2, 3 and 8), Class II HDACs, which are subdivided into two families, Class IIa (HDAC4, 5, 7 and 9) and Class IIb (HDAC6 and 10) and Class III HDACs, also named sirtuins, which comprises Sirt1, 2, 3, 4, 5, 6 and 7. In contrast to other HDACs, Class IIa HDACs are expressed in a tissue specific manner and have been shown to play an important role in cell differentiation. The hematopoietic system is a complex and interesting model of cell commitment and differentiation. Hematopoietic lineages are specified by lineage-restricted transcription factors that result in a distinct gene expression pattern. However, little is known about the role of chromatin modifying enzymes in the hematopoietic system. It has been shown that HDAC5 and HDAC9 are expressed in hematopoietic cells. However, their role in commitment of hematopoietic cells has never been investigated. Here, I propose to study the role of HDAC5 and HDAC9 in lineage commitment of hematopoietic cells. By using a genomic approach, as well as, knock out and trangenic mouse models, I will elucidate the lineage compartment where they are expressed, the specific target genes repressed by both proteins and their role in hematopoietic cell differentiation. The elucidation of the molecular mechanisms involved in the lineage commitment of hematopoietic stem cells will suppose an important advance in regenerative medicine.

Call for proposal

See other projects for this call



Avenida gran via hospitalet 199-203
08908 L'hospitalet de llobregat

See on map

Este Cataluña Barcelona
Activity type
Research Organisations
Administrative Contact
Carole Amroune (Ms.)
EU contribution
No data

Participants (1)